Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

TArgeting Multiphosphorylated tau in Blood for non-invasive Alzheimer's Disease diagnosis and staging

Project description

New blood test for early detection and staging of Alzheimer’s disease

Tau is a protein that stabilises neuronal cells, but in Alzheimer’s disease (AD), it becomes abnormally modified, forming tangles that disrupt brain function. The detection of specific, disease-associated forms of Tau in blood or cerebrospinal fluid has emerged as a promising avenue for diagnosis of AD at an early stage and for monitoring disease progression. With the support of the Marie Skłodowska-Curie Actions programme, the TAMBO-AD project aims to develop ultra-sensitive tests to detect Tau proteoforms that are simultaneously phosphorylated at two distinct sites. Researchers will validate these biomarkers in patient samples and proceed with developing portable, easy-to-use formats. The project has the potential to advance AD diagnosis in underserved regions.

Objective

Alzheimer's disease (AD) is the major cause of dementia. The disease has an escalating impact on public health due to an increasing prevalence among the aging population in Europe and globally. In light of the first disease-modifying therapies becoming available, early diagnosis and precise disease staging are crucial for timely implementation of the treatment strategy. In TAMBO-AD, I will build on my preliminary findings to leverage AD biomarker potential of tau simultaneously phosphorylated at two distinct sites. By combining my expertise in immunoassay development with the top technology available at the host institution, I will develop three novel Single Molecule Array (Simoa®) assays targeting p-tau217&231, p-tau205&217, and p-tau205&231. Through cerebrospinal fluid and plasma measurements in the Amsterdam Dementia Cohort, I will evaluate performance of all three p-tau forms as: 1) early diagnostic and 2) disease-staging biomarkers. For the best-performing plasma biomarkers, I will translate Simoa® assays into innovative fiber optic nanogold-linked immunosorbent assay format (FONLISA), which enables point-of-care testing. New point-of-care testing assays will maximize biomarker testing accessibility, enabling use in primary care centers and in remote or resource-limited areas. Finally, I will communicate the project and disseminate results in English and Polish during an intersectoral secondment at the patient organization — Alzheimer Europe. The TAMBO-AD project represents a pivotal opportunity to advance my research, grow professional network, and gradually become an independent researcher.

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

STICHTING AMSTERDAM UMC
Net EU contribution
€ 217 076,16
Total cost
No data

Partners (1)